TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.98 USD | -1.89% |
|
+1.16% | -18.15% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| Apr. 18 | Sector Update: Health Care | MT |
Presenter SpeechMichael Weiss (Executives)Okay. So we're going to get started here. I'm going ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.25
USD
Average target price
29.75
USD
Spread / Average Target
+108.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.15% | 2.2B | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- Transcript : TG Therapeutics, Inc. - Shareholder/Analyst Call
